Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease

OBJECTIVE: To analyze the preoperative plasma antigenic concentration and activity of von Willebrand factor and its main cleaving protease ADAMTS-13 in pediatric patients with cyanotic congenital heart disease undergoing surgical treatment and investigate possible correlations with postoperative bleeding. METHODS: Plasma antigenic concentrations (von Willebrand factor:Ag and ADAMTS-13:Ag) were measured using enzyme-linked immunoassays. Collagen-binding assays were developed to measure biological activities (von Willebrand factor:collagen binding and ADAMTS-13 activity). The multimeric structure of von Willebrand factor was analyzed using Western immunoblotting. Demographic, diagnostic, and general and specific laboratory data and surgery-related variables were subjected to univariate, bivariate, and multivariate analysis for the prediction of postoperative bleeding. RESULTS: Forty-eight patients were enrolled, with ages ranging from 9 months to 7.6 years (median 2.5 years). The plasma concentrations of von Willebrand factor:Ag and ADAMTS-13:Ag were decreased by 65 and 82%, respectively, in the patients compared with the controls (p<0.001). An increased density of low-molecular-weight fractions of von Willebrand factor, which are suggestive of proteolytic degradation (p = 0.0081), was associated with decreased ADAMTS-13 activity, which was likely due to ADAMTS-13 consumption (71% of controls, p = 0.0029) and decreased von Willebrand factor:collagen binding (76% of controls, p = 0.0004). Significant postoperative bleeding occurred in 13 patients. The preoperative ADAMTS-13 activity of <64.6% (mean level for the group), preoperative activated partial thromboplastin time, and the need for cardiopulmonary bypass were characterized as independent risk factors for postoperative bleeding, with respective hazard ratios of 22.35 (95% CI 1.69 to 294.79), 1.096 (95% CI 1.016 to 1.183), and 37.43 (95% CI 1.79 to 782.73). CONCLUSION: Low plasma ADAMTS-13 activity is a risk factor for postoperative bleeding in children with cyanotic congenital heart disease, particularly in children undergoing cardiopulmonary bypass.

[1]  A. Kaider,et al.  Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis , 2009, Thrombosis and Haemostasis.

[2]  J. Deckers,et al.  Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. , 2009, Atherosclerosis.

[3]  Ji-Eun Kim,et al.  Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. , 2009, Thrombosis research.

[4]  Z. Prohászka,et al.  Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia , 2009, Thrombosis and Haemostasis.

[5]  M. Bauer,et al.  Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure , 2009, Thrombosis and Haemostasis.

[6]  M. Woodward,et al.  Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack , 2008, Journal of thrombosis and haemostasis : JTH.

[7]  J. Child,et al.  Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. , 2006, The American journal of cardiology.

[8]  Toshio Mori,et al.  Localization of ADAMTS13 to the stellate cells of human liver. , 2005, Blood.

[9]  P. Mannucci,et al.  Opposite changes of ADAMTS‐13 and von Willebrand factor after cardiac surgery , 2005, Journal of thrombosis and haemostasis : JTH.

[10]  J. Moake.  von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. , 2004, Seminars in hematology.

[11]  A. Lopes,et al.  A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[12]  G. White,et al.  Clinical Use of a Rapid Collagen Binding Assay for von Willebrand Factor Cleaving Protease in Patients with Thrombotic Thrombocytopenic Purpura , 2002, Thrombosis and Haemostasis.

[13]  A. Sala,et al.  Proteolysis of von Willebrand Factor and Shear Stress–Induced Platelet Aggregation in Patients With Aortic Valve Stenosis , 2000, Circulation.

[14]  D. Devine,et al.  Hemostatic Parameters and Platelet Activation Marker Expression in Cyanotic and Acyanotic Pediatric Patients Undergoing Cardiac Surgery in the Presence of Tranexamic Acid , 2000, Thrombosis and Haemostasis.

[15]  H. Schwarz,et al.  The determination of von Willebrand factor activity by collagen binding assay , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  R. Marchant,et al.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. , 1996, Blood.

[17]  M. Seear,et al.  The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. , 1996, The Journal of thoracic and cardiovascular surgery.

[18]  T. Mayadas,et al.  Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. , 1996, The Journal of clinical investigation.

[19]  Y. Ikeda,et al.  Characterization of the Unique Mechanism Mediating the Shear-dependent Binding of Soluble von Willebrand Factor to Platelets (*) , 1995, The Journal of Biological Chemistry.

[20]  P. Mannucci,et al.  Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. , 1993, Blood.

[21]  S. Berkowitz,et al.  Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. , 1992, Blood.

[22]  J. Pober,et al.  IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. , 1989, Journal of immunology.

[23]  A. Schorer,et al.  Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells , 1987, British journal of haematology.

[24]  C. Francis,et al.  Fibrin induces release of von Willebrand factor from endothelial cells. , 1987, The Journal of clinical investigation.